Gamma-delta T-cell medicines
Oncology
UndisclosedPartnership with Immatics N.V.
Key Facts
About Editas Medicine
Editas Medicine is a leader in the CRISPR gene editing space, aiming to discover, develop, manufacture, and commercialize a robust pipeline of genomic medicines. The company leverages two distinct CRISPR nucleases, Cas9 and Cas12a, to access a broad range of genetic mutations and develop targeted in vivo therapies. Its strategic focus includes hemoglobinopathies, in vivo editing of hematopoietic stem cells and liver, and advancing cellular therapy assets through key partnerships with Bristol-Myers Squibb and Immatics N.V.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Mvasi (bevacizumab biosimilar) | Viatris | Approved |
| DRL-17822 | Dr. Reddy's Laboratories | Phase 2 |
| Biosimilar Portfolio | Zydus Lifesciences | Various |
| therascreen Solid Tumor | Qiagen | Commercial |
| GBR 830 | Glenmark Pharmaceuticals | Phase 1 |
| Bevacizumab Biosimilar | Glenmark Pharmaceuticals | Approved |
| Biosimilar (Bevacizumab) | Ipca Laboratories | Development |
| LockBody Platform Assets | Centessa Pharmaceuticals | Pre-clinical |
| Everolimus | Amneal Pharmaceuticals | Approved |
| Lenalidomide (Revlimid generic) | Amneal Pharmaceuticals | Approved |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | Approved |
| Pemrydi RTU | Amneal Pharmaceuticals | Approved |